IN2014CN04009A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04009A
IN2014CN04009A IN4009CHN2014A IN2014CN04009A IN 2014CN04009 A IN2014CN04009 A IN 2014CN04009A IN 4009CHN2014 A IN4009CHN2014 A IN 4009CHN2014A IN 2014CN04009 A IN2014CN04009 A IN 2014CN04009A
Authority
IN
India
Prior art keywords
apoaequorin
neurons
subject
injury due
neuronal injury
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Y Underwood
James R Moyer
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of IN2014CN04009A publication Critical patent/IN2014CN04009A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN4009CHN2014 2011-11-15 2012-11-15 IN2014CN04009A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
PCT/US2012/065291 WO2013074798A1 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Publications (1)

Publication Number Publication Date
IN2014CN04009A true IN2014CN04009A (zh) 2015-10-23

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4009CHN2014 IN2014CN04009A (zh) 2011-11-15 2012-11-15

Country Status (24)

Country Link
US (1) US20140294874A1 (zh)
EP (1) EP2780027B1 (zh)
JP (1) JP6181061B2 (zh)
KR (1) KR102009932B1 (zh)
CN (1) CN104244966B (zh)
AU (1) AU2012340446B2 (zh)
BR (1) BR112014011630A2 (zh)
CA (1) CA2855719C (zh)
CY (1) CY1119300T1 (zh)
DK (1) DK2780027T3 (zh)
ES (1) ES2643392T3 (zh)
HK (1) HK1202417A1 (zh)
HR (1) HRP20171532T1 (zh)
HU (1) HUE035017T2 (zh)
IL (1) IL232494B (zh)
IN (1) IN2014CN04009A (zh)
LT (1) LT2780027T (zh)
MX (1) MX350259B (zh)
PL (1) PL2780027T3 (zh)
PT (1) PT2780027T (zh)
SG (1) SG11201402364WA (zh)
SI (1) SI2780027T1 (zh)
WO (1) WO2013074798A1 (zh)
ZA (1) ZA201403577B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
IL265515B (en) * 2016-09-23 2022-09-01 Quincy Bioscience Llc Preparations that include apoquerin and vitamin D and methods of using them
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
CN102137681B (zh) * 2008-08-08 2014-12-03 埃姆诺医药有限公司 抗胰腺癌抗体
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Also Published As

Publication number Publication date
CA2855719A1 (en) 2013-05-23
HRP20171532T1 (hr) 2017-11-17
DK2780027T3 (en) 2017-09-25
JP2014533692A (ja) 2014-12-15
AU2012340446B2 (en) 2017-08-31
CA2855719C (en) 2021-10-26
WO2013074798A1 (en) 2013-05-23
HK1202417A1 (zh) 2015-10-02
US20140294874A1 (en) 2014-10-02
EP2780027A1 (en) 2014-09-24
KR20140097369A (ko) 2014-08-06
LT2780027T (lt) 2017-10-25
CN104244966B (zh) 2019-01-11
MX2014005798A (es) 2014-05-30
HUE035017T2 (en) 2018-03-28
EP2780027B1 (en) 2017-07-19
CN104244966A (zh) 2014-12-24
MX350259B (es) 2017-08-31
BR112014011630A2 (pt) 2017-06-27
ES2643392T3 (es) 2017-11-22
CY1119300T1 (el) 2018-02-14
SI2780027T1 (sl) 2017-11-30
AU2012340446A1 (en) 2014-05-29
PT2780027T (pt) 2017-10-04
IL232494A0 (en) 2014-06-30
KR102009932B1 (ko) 2019-08-12
NZ624736A (en) 2016-05-27
SG11201402364WA (en) 2014-09-26
PL2780027T3 (pl) 2017-11-30
ZA201403577B (en) 2015-07-29
IL232494B (en) 2019-03-31
JP6181061B2 (ja) 2017-08-16

Similar Documents

Publication Publication Date Title
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
IN2014DN09434A (zh)
MX2021001982A (es) Administracion local y concomitante de nanoportadores sinteticos, tolerogenicos para reducir la hipersensibilidad tipo i y tipo iv.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MY166014A (en) Combination therapy methods for treating proliferative diseases
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX2019009437A (es) Tratamiento de mielosupresion.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
NZ631144A (en) Compositions and methods for transmucosal absorption
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX348708B (es) Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato.
IN2015DN03854A (zh)
MX336347B (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
IN2014CN04009A (zh)
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
IN2014DN03010A (zh)
MX362905B (es) Tratamiento de combinacion.